Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > Wait - Wait - Wait

<< Previous

Bullboard Posts

Next >>

Post by bluemoons20on Jun 08, 2023 9:00am

129 Views

Post# 35486152

Wait - Wait - Wait

Even the gamblers are seemingly tired of the waiting and have deserted the ship. Given the years of waiting that longer term shareholders have endured so far , I guess a few more weeks are managable though perhaps frustrating.

Lets hope everyones expectations are exceeded!!

GLTA

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario